Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women’s health, wound, and other care products under the Listerine, Johnson’s, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Brand Resilience | Explore Kenvue's portfolio of iconic consumer health brands and their performance across diverse market segments, showcasing strengths and challenges |
Strategic Transformation | Delve into Kenvue's transition to a consumer-led approach, focusing on marketing investments and innovation to drive growth post-Johnson & Johnson spinoff |
Segment Performance | Uncover the contrasting dynamics of Kenvue's business segments, with Self Care and Essential Health showing resilience while Skin Health & Beauty faces headwinds |
Future Prospects | Analysts project modest growth with EPS estimates of $1.14 for FY1 and $1.21 for FY2, with price targets ranging from $21 to $29, reflecting varied outlooks |
Metrics to compare | KVUE | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipKVUEPeersSector | |
---|---|---|---|---|
P/E Ratio | 29.2x | 28.8x | 12.1x | |
PEG Ratio | 1.01 | 0.44 | 0.03 | |
Price/Book | 3.9x | 2.8x | 1.5x | |
Price / LTM Sales | 2.7x | 2.1x | 0.9x | |
Upside (Analyst Target) | 4.9% | 76.8% | 14.7% | |
Fair Value Upside | Unlock | 2.9% | 9.9% | Unlock |